UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0058
Expires: February 28, 2022
Estimated average
burden hours per
response. 2.50

FORM 12b-25

SEC FILE NUMBER 333-68008

					[CUSIP NUMBER
NOTIFICATION OF LATE FILING						71715X104
(Check one):	[_] Form 10-K [_] Form N-SAR	[_] Form 20-F [_] Form N-CSR	[_] Form 11-K [_] Form N-CEN	[X] Form 10-Q	[_] Form 10-D	
	Transition Rep	ort on Form 10-K ort on Form 20-F ort on Form 11-K ort on Form 10-Q ort on Form N-SAR ort on Form N-CEN				
If the notification re	For the Transition elates to a portion of the fil		dentify the Item(s) to	which the notification	relates:	
	·	P	ART I — REGISTR	ANT INFORMATIO)N	
		1 2	KI I— KEGISIK	ANTINFORMATIC	71 1	
PharmaCyte Biote Full Name of Regis						
.						
Former Name if Ap	plicable					
23046 Avenida de l	a Carlota, Suite 600					
	al Executive Office (Street	and Number)				_
Laguna Hills, CA 9	2653					
City, State and Zip	Code					
			PART II — RULES	S 12b-25(b) AND (c)		
(Check box if appro (a) The rea (b) The su [X] thereof subject	opriate) ason described in reasonab abject annual report, semi-	ole detail in Part III of annual report, transi- re the fifteenth calence rm 10-D,or portion the	this form could not be tion report on Form dar day following the ereof, will be filed on	the eliminated without 10-K, Form 20-F, For prescribed due date; or before the fifth cal	unreasonable effort or ex rm 11-K, Form N-SAR, or the subject quarterly lendar day following the	, Form N-CEN or Form N-CSR, or portion report or transition report on Form 10-Q or

PART III — NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, N-CEN or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has experienced a delay in completing the necessary disclosures and finalizing its financial statements with its independent public accounting firm in connection with its Quarterly Report on Form 10-Q for the period ended October 31, 2019 ("Quarterly Report"). As a result of this delay, the Registrant is unable to file the Quarterly Report by the prescribed filing date without unreasonable effort and expense.

PART IV — OTHER INFORMATION

(1)	Name and telephone number of person to contact in regard to this notification										
	К	Lenneth L. Waggoner	917	595-2850							
		(Name)		(Area Code)	(Telephone Number)						
(2)	Have all other periodic reports required the preceding 12 months or for such sho	` /	e e) during					
					Yes [X]	NO []					
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?										
					Yes [_]	NO [X]					
	If so, attach an explanation of the anticip cannot be made.	pated change, both narratively	and quantitatively, and, if app	propriate, state the reasons why a	reasonable estimate of the	results					
		Phar	maCyte Biotech, Inc.								
has cau	used this notification to be signed on its bel	` `	gistrant as Specified in Charto to duly authorized.	er)							
Date:	December 13, 2019	Bv·	/s/ Kenneth L. Waggoner								

Chief Executive Officer